Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma

References

• HerrmannAHosterEZwingersTImprovement of overall survival in advanced stage mantle cell lymphomaJ Clin Oncol200927451151819075279
   PubMed Web of Science ®Google Scholar
• VoseJMMantle cell lymphoma: 2013 update on diagnosis, risk- stratification, and clinical managementAm J Hematol201388121082108824273091
   PubMedGoogle Scholar
• WilliamsMETransplantation for mantle cell lymphoma: is it the right thing to do?Hematology Am Soc Hematol Educ Program2013201356857424319233
   PubMed Web of Science ®Google Scholar
• LeeMYTanTDFengACLiuMCClinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institutionAm J Hematol200681856857516823825
   PubMed Web of Science ®Google Scholar
• WangJFWangYZChenZWTaylorRCPrevalence of lymphoma subtypes in Shanxi according to latest WHO classificationZhonghua Bing Li Xue Za Zhi2006354218223 Chinese16776979
   PubMedGoogle Scholar
• No authors listedThe World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entitiesPathol Int200050969670211012982
   PubMed Web of Science ®Google Scholar
• KoYHKimCWParkCSREAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic featuresCancer19988348068129708949
   PubMed Web of Science ®Google Scholar
• VeldersGAKluin-NelemansJCDe BoerCJMantle-cell lymphoma: a population-based clinical studyJ Clin Oncol1996144126912748648383
   PubMed Web of Science ®Google Scholar
• Cancer Research UKMantle cell lymphoma2014 Available from: http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/about/types/mantle-cell-lymphomaAccessed May 5, 2016
   Google Scholar
• No authors listedA clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphomaBlood19978911390939189166827
   PubMed Web of Science ®Google Scholar
• ZhouYWangHFangWIncidence trends of mantle cell lymphoma in the United States between 1992 and 2004Cancer2008113479179818615506
   PubMed Web of Science ®Google Scholar
• ChuangSSHuangWTHsiehPPMantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2Pathol Int200656844044816872438
   PubMed Web of Science ®Google Scholar
• HowardOMGribbenJGNeubergDSRituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survivalJ Clin Oncol20022051288129411870171
   PubMed Web of Science ®Google Scholar
• YingZTZhengWWangXPThe clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphomaChin J Cancer201231734835322704490
   PubMedGoogle Scholar
• MiuraKTakasakiHTsujimuraHDoes more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in JapanInt J Hematol201193568468621479980
   PubMed Web of Science ®Google Scholar
• ChiharaDAsanoNOhmachiKPrognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in JapanBr J Haematol2015170565766825953436
   PubMed Web of Science ®Google Scholar
• DreylingMThieblemontCGallaminiAESMO consensus conferences: guidelines on malignant lymphoma – part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphomaAnn Oncol201324485787723425945
   PubMed Web of Science ®Google Scholar
• McKayPLeachMJacksonRCookGRuleSGuidelines for the investigation and management of mantle cell lymphomaBr J Haematol2012159440542622994971
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN clinical practice guidelines in oncology (NCCN guidelines): non-Hodgkin’s lymphomas. Version 42014 Available from: https://www.nccn.org/about/nhl.pdfAccessed February 6, 2018
   Google Scholar
• RobakTHuangHJinJBortezomib-based therapy for newly diagnosed mantle-cell lymphomaN Engl J Med20153721094495325738670
   PubMed Web of Science ®Google Scholar
• Velcade (bortezomib) for injection: for subcutaneous or intravenous use [prescribing information]Cambridge (MA)Millennium Pharmaceuticals2014
   Google Scholar
• MounierNRibragVHaiounCAll B lymphoma subtypes do not share similar outcome after frontline R-CHOP plus bortezomib treatment: a randomized phase 2 trial from Groupe d’Etude des Lymphomes de l’Adulte (GELA)Ann Oncol200819Suppl 413517962207
   PubMed Web of Science ®Google Scholar
• HeJYangLHanXThe choice of regimens based on bortezomib for patients with newly diagnosed multiple myelomaPLoS One201496e9917424918626
   PubMed Web of Science ®Google Scholar
• LinMHouJChenWImproved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patientsAdv Ther201431101082109425331616
   PubMed Web of Science ®Google Scholar
• WangHWangLLuYLong-term outcomes of different bortezomib-based regimens in Chinese myeloma patientsOnco Targets Ther2016958759526869803
   PubMed Web of Science ®Google Scholar
• IgarashiNChouTHiroseTImaiYIshiguroTBortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experienceInt J Hematol201092351852320886379
   PubMed Web of Science ®Google Scholar
• MiyakoshiSKamiMYujiKSevere pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myelomaBlood200610793492349416410442
   PubMed Web of Science ®Google Scholar
• GotohAOhyashikiKOshimiKLung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the “lung injury by bortezomib” joint committee of the Japanese Society of Hematology and the Japanese Society of Clinical HematologyInt J Hematol200684540641217189220
   PubMed Web of Science ®Google Scholar
• VenkatakrishnanKBurgessCGuptaNToward optimum benefit-risk and reduced access lag for cancer drugs in Asia: a global development framework guided by clinical pharmacology principlesClin Transl Sci20169192226836226
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteCommon terminology criteria for adverse events2006 Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfAccessed January 19, 2018
   Google Scholar
• DetermannOHosterEOttGKi-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study GroupBlood200811142385238718077791
   PubMed Web of Science ®Google Scholar
• FlinnIWvan der JagtRKahlBSRandomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studyBlood2014123192944295224591201
   PubMed Web of Science ®Google Scholar
• Kluin-NelemansHCHosterEHermineOTreatment of older patients with mantle-cell lymphomaN Engl J Med2012367652053122873532
   PubMed Web of Science ®Google Scholar
• LenzGDreylingMHosterEImmunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)J Clin Oncol20052391984199215668467
   PubMed Web of Science ®Google Scholar
• FisherRIBernsteinSHKahlBSMulticenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaJ Clin Oncol200624304867487417001068
   PubMed Web of Science ®Google Scholar
• GoyABernsteinSHKahlBSBortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE studyAnn Oncol200920352052519074748
   PubMed Web of Science ®Google Scholar
• KaneRCDagherRFarrellABortezomib for the treatment of mantle cell lymphomaClin Cancer Res20071318 Pt 15291529417875757
   PubMed Web of Science ®Google Scholar
• O’ConnorOAMoskowitzCPortlockCPatients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trialBr J Haematol20091451343919220284
   PubMed Web of Science ®Google Scholar
• BroylACorthalsSLJongenJLMechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trialLancet Oncol201011111057106520864405
   PubMed Web of Science ®Google Scholar
• LonialSRichardsonPGSanMJCharacterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaBr J Haematol2008143222222918713253
   PubMed Web of Science ®Google Scholar
• FurmanRRMartinPRuanJPhase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphomaCancer2010116235432543920665890
   PubMed Web of Science ®Google Scholar
• GoyABernsteinSHMcDonaldAPotential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trialLeuk Lymphoma20105171269127720572799
   PubMed Web of Science ®Google Scholar
• HosterEKlapperWHermineOConfirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma NetworkJ Clin Oncol201432131338134624687837
   PubMed Web of Science ®Google Scholar
• RummelMJNiederleNMaschmeyerGBendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialLancet201338198731203121023433739
   PubMed Web of Science ®Google Scholar
• RibragVGisselbrechtCHaiounCEfficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma study group (GELA)Cancer2009115194540454619593797
   PubMed Web of Science ®Google Scholar